US FDA approves Awiqli weekly insulin for children with type 2 diabetes

The US Food and Drug Administration has approved Awiqli (icodec-abae) weekly insulin at a concentration of 700 units per mL for children aged 10 years and older with type 2 diabetes. Novo Nordisk announced the approval and described Awiqli as the first and only once-weekly option for this group.

AI-written summary of 2 sources; every verified point is backed by a verbatim quote. How Iyan works

• The approval applies to children aged 10 years and older with type 2 diabetes.

  «for children aged 10 years and older with type 2 diabetes, Novo Nordisk announced»

  Healio • AOL
• The company described the drug as the first and only once-weekly option for children aged 10 years and older with type 2 diabetes.

  «as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes»

  AOL
• The approved concentration is 700 units per mL of icodec-abae insulin.

  «insulin icodec-abae 700 U/mL for children aged 10 years and older with type 2 diabetes»

  Healio • AOL

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms